2 Minutes with Joey - HIMS Stock News

Epizódy

• HIMS Today - Jul 19: Debt Raise Drags Stock Down 19.07.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor, and today we’re breaking down Hims & Hers, or HIMS for short. Today was a red day for the stock, dropping about 2.5%. Yeah, that one stung.So, what happened? HIMS took a hit today, and it’s all tied to some news about raising debt. They’re looking to bulk up $350 million to help fund their buyout of Eucalyptus and push their AI initiatives. Sounds ambitious, right? But when companies start piling on debt, investors can get a little nervous, and it seems like that’s what happened here. People hit the sell button fast, and the stock felt the burn.Now, why did this debt raise get everyone riled up? Well, it’s a mix of factors. First off, the market’s been a bit shaky, and anytime a company raises that kind of cash through debt, it raises some eyebrows. It’s like, “Whoa, are they in trouble?” Plus, there’s chatter about inflation and how it’s impacting stocks across the board, including HIMS. So, with all this going on, it’s no wonder folks are feeling skittish.On top of that, there’s a lot of talk about HIMS’ potential in the health tech space, especially with AI. They’ve got big plans, including eyeing a heart attack prediction firm, which could be a game-changer if it all works out. But right now, it seems like the debt news overshadowed that excitement.One thing to keep an eye on is how this debt raise affects their future moves. If they can turn this investment into growth, it might pay off down the line. But for now, it’s a wait-and-see game.So, to wrap it up, HIMS had a rough day with that debt news weighing heavy on the stock. It’s definitely a mixed bag with some potential on the horizon, but the market’s feeling a bit cautious right now. Just remember, I’m here for the info and entertainment, not giving any financial advice. Catch you later!
• HIMS Today - Jul 18: FDA Warning Hits Stock 18.07.2026 1min

  Hey there! It’s Joey, your go-to guy for stock talk. I’ve been in the investing game for a while, and today we're diving into Hims & Hers, which had a rough day. The stock dipped about 2.5%, closing at $32.84. So, what went down? Well, HIMS got smoked after some FDA news. They warned telehealth companies, including HIMS, over claims related to GLP-1 medications. Yeah, that one stung. Traders were spooked, and you could see it in the volume—almost 10 million shares changed hands, which is a bit lighter than usual but still pretty active!Now, why did this happen? The FDA is cracking down on misleading claims, and HIMS being in the spotlight made folks nervous about future sales and growth. There’s this whole "overhang" vibe in the market right now. Traders think this might blow over eventually, but who really knows? It's all about how HIMS responds to this FDA warning moving forward.Also, interesting tidbit: HIMS just said goodbye to their Chief Accounting Officer, Irene Beckl. Not sure if that’s related, but it’s something to keep an eye on. Changes in leadership can stir up some uncertainty for investors.Looking ahead, there’s chatter about the stock being potentially undervalued. Some folks are saying it could be 81% undervalued after those privacy claims came out. So, while today was rough, there’s a glimmer of hope in the analysts' outlooks. Alright, that’s the scoop on Hims & Hers today! Remember, this is just for info and fun. Always do your own research before making any moves. Catch you later!
• HIMS Today - Jul 17: Short Bets Burned 17.07.2026 1min

  Hey there! It’s Joey, your friendly longtime investor here to break down what went down with Hims & Hers today. So, HIMS had a bit of a red day, slipping down by almost two-tenths of a percent. Yeah, that one stung a little.Now, let’s talk about what happened. HIMS has been riding this wild wave lately, especially after some big news from Novo Nordisk that sent their stock soaring. But today? It was a different story. The stock kinda just sat there, barely moving, even with all that buzz still hanging around. Volume was way under average too, which is usually a sign that folks are just sitting on their hands.So why the dip? Well, some chatter out there suggests that after that explosive run, some investors might be taking profits. I mean, who wouldn't want to cash in after a big win, right? Plus, there’s been this ongoing conversation about GLP-1 drugs and how it might already be priced into the stock. People are kinda wondering if HIMS has already felt the impact of that news, and honestly, nobody really knows for sure. Oh, and here’s something interesting on the horizon: there are whispers that HIMS could still be undervalued, even after all this action. Some analysts are saying it might be sitting at around 81% undervalued based on privacy claims. So, there could still be some potential upside for those who are eyeing it.Anyway, that’s the scoop for today. Just remember, this is all for your info and entertainment. I’m not here to tell you what to do with your money. Always do your own thing. Catch you later!
• HIMS Today - Jul 16: Peptide Push Amid FDA Scrutiny 16.07.2026 1min

  Hey there! It’s Joey, your friendly investor here, breaking down today’s moves in the market. So let’s talk about Hims & Hers, or HIMS for short. Today wasn’t a great day for them; the stock dipped about 2.9%. Ouch, right?So, what happened? HIMS started off with some hope but ended up getting smoked. It was a bit of a rollercoaster, honestly. The volume was way below average, which usually means folks were a little hesitant to jump in. Now, why did this happen? Well, there’s a lot going on in the background. HIMS has been making noise about their peptide products, especially with some recent signals from RFK Jr. hinting at potential clearances. That could’ve been a game-changer, but the excitement seems to have fizzled out a bit today. Plus, there’s some FDA scrutiny looming over their peptide push, which has definitely got investors on edge. It’s like waiting for a text back from someone you really like—nail-biting!Also, the stock had a solid gain of 6.2% earlier in the week, so maybe some people were just cashing in on those gains. It’s kinda like when you hit a lucky streak at the arcade, and you decide to trade in your tickets while you’re ahead. But then, bam! The momentum shifted, and that one stung.Looking ahead, HIMS is gearing up for a key FDA meeting soon. That’s definitely something to keep an eye on, as it could shake things up again. So, to wrap it all up, HIMS had a rough day, but with the peptide news and the FDA meeting coming up, it’s a mixed bag of potential for the future. Remember, this is just me sharing what I see, not financial advice or anything. Stay savvy out there, folks! Catch you later!
• HIMS Today - Jul 15: New Partners Fuel Growth 15.07.2026 1min

  Hey there! It's Joey, your friendly neighborhood investor, here to break down today’s stock action. We’re talking about Hims & Hers, and guess what? It was a green day! The stock popped up about 4.25%. Not too shabby, right?So, what went down? HIMS had a pretty solid day, bouncing back with some nice gains. You know how it is—some days you're riding high, and other days, it feels like you’re just trying to keep your head above water. Today, though? It was all about those gains.Now, why did it happen? Well, there’s a lot of buzz around Hims right now. They’ve got eight new partners on board, which is fueling their push to create this all-in-one health platform. Sounds ambitious, right? But hey, if you’re gonna dream, dream big! Also, their CEO is eyeing a heart attack prediction firm, which he thinks has "unreal" value. That’s got investors feeling optimistic. On top of that, they’re gearing up for a call on August 10 to discuss their latest health platform results. So, there’s definitely a lot of action happening behind the scenes.But it’s not all sunshine and rainbows. There’s some FDA scrutiny on their peptide products, and Citi just dropped a note saying there’s a “big caveat” to Amazon’s GLP-1 push that could impact HIMS. So, while things are looking good now, there are some potential bumps in the road to keep an eye on. So, what’s the takeaway? Hims & Hers is in the spotlight with some new partnerships and ambitious plans, but they’ve got some challenges ahead too. Just a friendly reminder that the market can be wild, so always keep that in mind!Alright, that’s a wrap for today! Just here to keep you in the loop, so remember, this isn’t financial advice—just some friendly info. Catch you later!
• HIMS Today - Jul 14: Amazon's GLP-1 War Hits HIMS 14.07.2026 1min

  Hey, what’s up? It’s Joey here, your friendly neighborhood investor breaking down today’s market moves. Let’s talk about Hims & Hers, or HIMS for short. Today was a bit of a rough ride; the stock was down about 1.19%. So, what happened? Well, it looks like HIMS got a little smoked after some news about Amazon ramping up its GLP-1 competition with Ozempic. Yeah, that one stung. Investors were clearly worried about how that might affect HIMS' growth, especially since they’re all about health and wellness products. When big players like Amazon step into the ring, it can get a bit dicey for smaller companies.Now, why did people hit the sell button so fast? There’s been chatter around the whole AI healthcare scene, and with earnings calls coming up, folks are on high alert. HIMS is set to drop their Q2 results on August 10, and everyone’s trying to figure out if they’ll impress or flop. Plus, there was some buzz about insider share sales, which usually raises eyebrows. It’s like a little red flag that makes people think twice before holding onto their shares.On a brighter note, HIMS did schedule that call to discuss their latest health platform results, which could be a big deal. If they have good stuff to share, it might just turn the tide for them. Just keep an eye on that.So yeah, that’s the scoop on HIMS today. It was a tough day, but these things happen in the market. Remember, I’m just here to share what’s happening, not to give any financial advice. Catch you later!
• HIMS Today - Jul 13: New Partners, FDA Meeting Buzz 13.07.2026 1min

  Hey, what’s up? It’s Joey here, your go-to guy for stock chatter. I’ve been investing for a while, and today we’re talking about Hims & Hers, or HIMS for short. It was a bit of a mixed bag today, barely up by about a third of a percent. Not a big move, but hey, at least it wasn’t a total flop.So, what went down? HIMS is trying to shake things up with eight new partnerships, aiming to build this all-in-one health platform. Sounds cool, right? But here’s the kicker: they just had their worst week in two months. Ouch. They’re also gearing up for a big FDA meeting about their peptides campaign, which could be a game-changer for them. Now, why the mixed vibes? Well, on one hand, those new partnerships are exciting and could signal growth, but on the flip side, there’s chatter about whether their GLP-1 strategy has backfired. That’s a fancy way of saying they might have bet on the wrong horse. Investors are probably feeling a bit jittery with all this back-and-forth. And just to keep it real, the volume today was way off compared to their average. Like, they only had about 1.6 million shares traded when they usually see over 16 million. That tells me people might be sitting on the sidelines, waiting to see how this FDA meeting goes. One thing worth keeping an eye on is that potential rally buzz. Some fund managers are saying HIMS could rally up to 60% this week if the stars align. I mean, that sounds great, but let’s keep those expectations in check, yeah?So, to wrap it up, HIMS is in a bit of a tug-of-war between new opportunities and some challenges. It’s definitely a wait-and-see moment. Just remember, this is all for info and fun, not financial advice. Catch you later!
• HIMS Today - Jul 12: Stock Takes a Hit 12.07.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor, here to break down what went down with Hims & Hers today. So, HIMS had a rough day, dropping about 3%. Yeah, that one stung.The stock opened lower and just kept slipping. By the end of the day, it was down to $34.38. The trading volume was pretty active, too, with nearly 12 million shares changing hands. Not super surprising since folks were clearly feeling the pressure.So, why the dip? Well, a few reasons popped up. First off, there’s this PPI report that’s making waves in the market. It’s got investors on edge about inflation and, honestly, that’s never a good vibe for stocks like HIMS. Plus, there’s chatter around their GLP-1 drug strategy. Some analysts are saying it might’ve backfired, which isn’t great news for the company’s future plans. And then there was that brutal Q1 report that left a bad taste in everyone's mouth. Just a perfect storm of negativity, really.Oh, and here’s a little nugget: some investors still think HIMS could turn things around with their partnerships with companies like Novo and Lilly. They’re even dubbing it the “Netflix of healthcare.” Sounds ambitious, right? But, hey, we’ll see how that plays out.So, yeah, a tough day for HIMS. But remember, this is just a snapshot of the moment. Stocks go up and down, and this is all just part of the wild ride of investing. Keep your head up, and thanks for hanging out with me today! Just a reminder, I’m here to share info and have fun, not to give you any financial advice. Catch you later!
• HIMS Today - Jul 11: Amazon's GLP-1 Moves Impact Stock 11.07.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor. Been in the game for a while and today we’re talking about Hims & Hers, ticker HIMS. Spoiler alert: it was a red day, down about 3%. Ouch!So, what went down? HIMS got smoked today, dropping a solid chunk of change. The stock dipped after Amazon decided to ramp up its game in the GLP-1 space, which is a big deal. These GLP-1 drugs, like Ozempic, have been the hot topic lately, and now with Amazon stepping in, it’s shaking things up a bit for HIMS.Now, why did this matter? Well, investors got a little spooked. Amazon’s entry into this market means more competition, and that can make people nervous about HIMS’ growth prospects. It’s like when your favorite pizza place suddenly has a new rival across the street – you start wondering if they’ll still get your business. Plus, Truist put a hold on HIMS, giving it a $23 target price, which isn’t exactly a vote of confidence. Combine that with some chatter about valuation concerns, and you’ve got a recipe for a sell-off.And here’s a fun fact to keep in mind: there’s been a lot of buzz around AI healthcare bets as earnings season approaches. That could shake things up for HIMS, too, especially with all the focus on tech in healthcare lately. So yeah, today was a bit rough for Hims & Hers. But hey, that’s how the market rolls sometimes. Just remember, this is all for info and entertainment. No financial advice here, just a friendly chat about stocks. Catch you later!
• HIMS Today - Jul 10: Stock Takes a Hit 10.07.2026 1min

  Hey there! It’s Joey here, your friendly neighborhood investor, breaking down what went down today in the stock world. Today’s focus is Hims & Hers, and it was a red day for them, down about 4.17%. Yeah, that one stung a bit.So, here’s the scoop. HIMS started off a bit shaky and just couldn’t catch a break. The volume was pretty low compared to usual, which usually isn’t a great sign. I mean, when people aren’t trading as much, it often means they’re not feeling too confident. Now, why the drop? A couple of things played into it. First off, Truist came out and said they’re sticking with a “Hold” rating on HIMS, throwing a $23 price target out there. With all the buzz around GLP-1 drugs, there’s some concern about how that’ll affect HIMS’s business model. Plus, there were some mixed signals from Citi, suggesting that while there’s a “big caveat” in Amazon’s GLP-1 push, it might limit risks for HIMS. But still, uncertainty is never good for stock prices, you know? Also, there was talk about HIMS bulking up their debt raise to $350 million for a buyout, and that usually makes investors a bit jittery. It’s like, “Why are you raising that much debt?” People want to see companies grow without piling on the loans. And with all this chatter about valuation and whether it's already too rich, it just added to the overall anxiety. Now, on the horizon, keep an eye out for any updates regarding their AI push and how that’s going to roll out. That could be a game-changer if they play their cards right.So, yeah, it was a tough day for HIMS. But that’s the market for you—up and down like a roller coaster. Just remember, this recap is for your info and entertainment, not financial advice. Catch you later!
• HIMS Today - Jul 09: Mixed Signals and New Partners 09.07.2026 1min

  Hey there! It’s Joey, your friendly neighborhood investor, here to break down what went down today with Hims & Hers, ticker HIMS. Spoiler alert: it was a red day, but just barely. The stock dipped 0.08%. Yeah, that one stung a bit.So, what happened? Well, HIMS opened lower and kinda just hung around that level all day. Trading volume was way off too, like, way below average. Usually, we see a lot more action, but today it felt like people were just sitting on their hands.Now, why did this happen? A few things are swirling around. BofA bumped up their price target for HIMS to $37, which sounds good, right? But despite that, investors seemed a bit hesitant. You know how it goes—sometimes even positive news doesn't light a fire under the stock. Plus, there’s chatter about Hims & Hers bringing on eight new partners to boost their health platform. That’s cool, but it seems like the market is still trying to wrap its head around all of it. Some folks think the market just doesn’t get the potential here yet.Also, there was some buzz about the CEO eyeing a heart attack prediction firm, which could be a game-changer. But again, the stock just didn’t react the way you might expect. It’s like people are waiting for something more concrete before jumping back in.Looking ahead, it’s worth noting that the overall sentiment seems mixed. Even with new partnerships and a higher target from BofA, there’s still a lot of skepticism floating around. So, folks are definitely watching closely to see if this turns into something more substantial.To wrap it up, Hims & Hers had a pretty uneventful day, but there’s some interesting stuff brewing under the surface. Keep your eyes peeled, and remember, this is just for fun and info, not financial advice. Catch ya later!
• HIMS Today - Jul 09: Stock Stagnates Despite Buzz 09.07.2026 1min

  Hey there! I’m Joey, your friendly neighborhood investor, here to break down what went down with Hims & Hers today. So, let’s talk about HIMS. Today was a pretty flat day for the stock—no movement, just hanging around at $36.07. Now, what’s the scoop? Well, it was a quiet day in terms of action. The stock didn’t really budge at all. I mean, zero percent change. It’s like it just decided to take a chill pill. Volume was way below average too, like people just weren’t that interested. So why the snooze-fest? A couple of things are worth mentioning. First off, BofA just raised their price target for HIMS to $37, which is a good sign, but apparently, that didn’t get anyone hyped. There are also mentions of new partnerships that could help Hims & Hers build this all-in-one health platform, which sounds cool, but again, no one seemed to care today. It’s like the market was just in a mood to ignore all the good news. And get this, there’s chatter about the CEO eyeing a heart attack prediction firm, which is kind of a big deal. People are saying that could add some serious value, but it looks like the stock didn’t catch the memo. Maybe folks are just waiting for real action instead of just talk.One thing to keep an eye on is that Hims & Hers is trying to expand its services, and they’ve got some new partners lined up. So, while today was a snoozer, there’s potential for some exciting stuff to come down the line. Alright, that’s a wrap for today! Just remember, I’m here to keep you in the loop, but this isn’t financial advice. Always do your own thing when it comes to investing. Catch you later!
• HIMS Today - Jul 08: CFO Sells Shares, Market Shrugs 08.07.2026 1min

  Hey there! It’s Joey here, your friendly market dude. I’ve been investing for a while, and today we’re checking out Hims & Hers, or HIMS for short. Spoiler alert: it was a red day, down just a bit at 36.07, losing about a quarter percent.So, what went down? Well, HIMS barely moved today, but it’s still got folks talking. The stock saw some action, but it didn’t really pop off like some people were hoping. The volume was lower than usual, which kinda hints that interest might be cooling off a bit. Now, let’s get into the why. There’s been some chatter about HIMS being undervalued. Articles are saying the market still doesn’t get the potential of their new products. Barclays even mentioned that the company is sitting on some serious opportunities that folks might be overlooking. But then, there’s the CFO, Okupe, who sold over $261k worth of shares today. That’s a head-scratcher, right? When the CFO cashes out, it raises some eyebrows. Maybe he’s just cashing in on some gains, but still, it’s a little suspicious for investors. Also, there’s some buzz comparing HIMS to Teladoc Health. It’s like a side-by-side showdown in the healthcare space. People are weighing the pros and cons, trying to figure out which stock’s the better bet. One more thing to keep in mind: the FDA has been asking some questions about HIMS’ peptides, which could be a factor in how investors are feeling about the company right now. It’s like waiting for the next episode of your favorite show – you’re not really sure how it’s going to play out.So, to wrap it up, HIMS had a slow day with some mixed signals in the air. The CFO’s stock sale and ongoing FDA inquiries are definitely on the minds of investors. Just remember, I’m here to keep you in the loop and share what’s happening, but this isn’t financial advice. Always do your own homework! Catch you later!
• HIMS Today - Jul 07: Obesity Drug Coverage Changes 07.07.2026 1min

  Hey there! It’s Joey, your friendly stock buddy. I’ve been in the investing game for a while, and today we’re talking about Hims & Hers, or HIMS for short. Spoiler alert: it was a red day, down about 3.16%. Ouch!So, what happened? HIMS started the day looking alright but ended up getting smoked. A lot of folks were hitting the sell button, and the volume was way down compared to the usual. Not a great look when people are usually buzzing about it. Now, why did this happen? Well, there’s a lot of chatter around the FDA and some questions about peptides. Apparently, some think HIMS could be undervalued, but that didn’t stop the stock from taking a hit today. Plus, there’s this whole situation with employers dropping coverage for obesity drugs, and some are thinking HIMS might come out ahead because of it. You know how it goes—one day you’re up, the next you’re down, and nobody really knows for sure why sometimes. On the horizon, HIMS is still being compared to other players like Teladoc. There’s a lot of buzz about how they stack up against each other, and with HIMS getting some love for being undervalued, it’s definitely something to keep an eye on. So yeah, tough day for HIMS, but there's still potential out there. Remember, I’m just here to share the info and keep it real. No financial advice, just a friendly chat about what’s going on. Catch you later!
• HIMS Today - Jul 06: Debt Raise and AI Push 06.07.2026 1min

  Hey there! I’m Joey, a longtime investor, and today we’re talking about Hims & Hers. So, it was a red day for HIMS, down about 3.34%. Yeah, it got smoked a bit.Now, here’s the scoop: HIMS started off strong but then took a dive. The big news? They’re bulking up on debt, raising it to $350 million for that Eucalyptus buyout and pushing into AI. It’s like they’re trying to level up their game, but not everyone’s feeling it. The stock had some serious swings, and it looks like folks were quick to hit that sell button.So, why did this happen? Well, the CEO’s been talking about how they’re betting on becoming the “gold standard” in healthcare over the next decade. Sounds ambitious, right? But then, there’s the debt thing. Some investors are feeling a bit uneasy about that. When you pile on debt, it can make people a little jittery. And while they secured a $400 million facility from JPMorgan, the mixed signals about the debt and the buyouts have left some scratching their heads.Also, don’t forget, they’re eyeing a heart attack prediction firm, which the CEO thinks has “unreal” value. That could be a game changer, but it’s still in the early stages, and who knows what’ll come of it.Just a heads up, earnings season is on the horizon for HIMS. That’ll be worth keeping an eye on since it could shake things up.Alright, that’s the lowdown on HIMS today. Just remember, I’m here to keep you informed and entertained, but this isn’t financial advice. Catch you later!